(2S)-2-amino-2-(1,3-benzothiazol-2-yl)propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-2-(1,3-benzothiazol-2-yl)propanoic acid
• 化学式: C₁₀H₁₀N₂O₂S
• 分子量: 222.27
• InChiKey: QUOIWJQFLBPHHH-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-LI PROTEIN/PROTEIN INTERACTIONS<br/>[FR] INHIBITEURS MACROCYCLIQUES DES INTERACTIONS PROTÉINE/PROTÉINE PD-1/PD-L1 ET CD80(B7-1)/PD-LI
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016039749A1

  公开（公告）日：2016-03-17

  The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

  本公开提供了一种新颖的大环肽，可以抑制PD-1/PD-L1和PD-L1/CD80蛋白质相互作用，因此可用于改善各种疾病，包括癌症和传染病。
• MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140294898A1

  公开（公告）日：2014-10-02

  The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

  本公开提供了新型大环肽，其能够抑制PD-1/PD-L1和PD-L1/CD80蛋白质/蛋白质相互作用，因此可用于改善各种疾病，包括癌症和传染性疾病。
• ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE
  申请人：EPO-Med Inc.

  公开号：EP3851448A1

  公开（公告）日：2021-07-21

  The present specification provides an anti-EpoR peptide. A peptide having the structure represented by formula (I): X1-SCH (A1) (A2) (A3) (A4) (A5) (A6)V(A7) (A8) -X2 (wherein X1 is the amino terminal side of the peptide; X2 is the carboxy terminal side of the peptide; A1 is M or F, phenylglycine or phenethylglycine optionally substituted by a halogen atom or a hydroxyl group; A2 is A, d-alanine or G; A3 is P, homoproline or A; A4 is M, L, A or I; A5 is T or A; A6 is M or W, F, Y, β-homotryptophan, α-naphthylalanine, β-naphthylalanine, or quinolylalanine optionally substituted by methyl or a halogen atom; A7 is C, homocysteine, or penicillamine; and A8 is K, R or absent.) is provided.

  本说明书提供了一种抗 EpoR 肽。具有式（I）所代表结构的多肽：X1-SCH（A1）（A2）（A3）（A4）（A5）（A6）V（A7）（A8）-X2（其中，X1是肽的氨基端侧；X2是肽的羧基端侧；A1是M或F、任选被卤原子或羟基取代的苯甘氨酸或苯乙基甘氨酸；A2是A、d-丙氨酸或G；A3 是 P、同脯氨酸或 A；A4 是 M、L、A 或 I；A5 是 T 或 A；A6 是 M 或 W、F、Y、β-高色氨酸、α-萘基丙氨酸、β-萘基丙氨酸或任选被甲基或卤原子取代的喹啉基丙氨酸；A7 是 C、同型半胱氨酸或青霉胺；以及 A8 是 K、R 或不存在。)提供。
• MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3191113B1

  公开（公告）日：2019-11-06
• MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-LI PROTEIN/PROTEIN INTERACTIONS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3191113A1

  公开（公告）日：2017-07-19